The Georgia Life Sciences staff believe that diversity, equity, and inclusion are fundamental to the progress and success of the life sciences industry. Our mission—improving access to innovative technologies and advancing the health and well-being of people worldwide—can only be fully realized when every voice is heard, valued, and respected.


We unequivocally denounce all forms of racism, discrimination, and hate. Our organization stands firmly against any actions or words that seek to divide us based on race, ethnicity, religion, gender, or any other identity. These values are non-negotiable and are central to who we are as an organization.

 

As we continue to advocate for the growth of Georgia’s life sciences economy, we are also committed to fostering an environment where diversity thrives, equity is pursued, and inclusion is practiced every day. We recognize that a diverse community of professionals brings a wealth of perspectives and ideas that drive innovation and excellence, which are critically important in healthcare.


To reinforce our commitment to these principles, Georgia Life Sciences is taking proactive steps to ensure that our organization not only talks about diversity, equity, and inclusion but lives by these values. These steps include:


  • Diverse Representation: We are committed to ensuring diverse representation across all levels of our organization, including our board, leadership, and membership.
  • Equitable Practices: We will continuously review and improve our policies to ensure they promote equity and fairness for all, particularly in our hiring practices, partnerships, and member services.
  • Inclusive Culture: We are dedicated to creating a culture where everyone feels welcome and respected. We will provide ongoing training and resources to our staff and members to build awareness and skills in areas of diversity, equity, and inclusion.
  • Community Engagement: We will actively engage with underrepresented communities to ensure their voices are included in shaping the future of the life sciences industry.

 

Georgia Life Sciences remains steadfast in its commitment to creating a more just and inclusive society. We understand that this is an ongoing journey, and we are fully dedicated to learning, growing, and taking the necessary actions to uphold our values.


We invite our members, partners, and stakeholders to join us in this important work. Together, we can build a life sciences community that truly reflects the diversity of the world we serve.

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: